CAPEGARD 500 Tablets are indicated for the first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with CAPEGARD 500 Tablets monotherapy. Use of CAPEGARD 500 Tablets instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage.
CAPEGARD 500 Tablets ....... Blister pack of 10 tablets